{"id":"W2946456966","doi":"10.1016/j.jtho.2019.05.010","title":"Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Astellas Pharma Global Development; Ipsen; Astellas Pharma; MedImmune; Daiichi-Sankyo; Celldex Therapeutics; Helsinn; University of Texas Southwestern Medical Center; Merck; Spectrum Pharmaceuticals; North Carolina GlaxoSmithKline Foundation; Novartis; Celgene; Pfizer; Biogen; GlaxoSmithKline; Roche; Takeda Pharmaceutical Company; AbbVie; Genentech; Aeglea BioTherapeutics; Biogen Idec; Merck Sharp and Dohme; Genzyme; Bayer Corporation; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Intuitive Surgical","keywords":"Medicine; Nivolumab; Clinical endpoint; Lung cancer; Quality of life (healthcare); Adverse effect; Internal medicine; Population; Incidence (geometry); Randomized controlled trial; Performance status; Cancer; Surgery; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006090255,0.0002702206,0.001205705,0.00028376,0.00007542903,0.000013099,0.00009665858,0.0001553726,0.00006576015],"category_scores_gemma":[0.00005504561,0.0001607387,0.00004256045,0.000444844,0.0001603987,0.00022439,0.00006095552,0.0004733393,3.056268e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006377441,"about_ca_system_score_gemma":0.001696439,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006299384,"about_ca_topic_score_gemma":0.0005908724,"domain_scores_codex":[0.9971253,0.0002349866,0.001399717,0.0003159348,0.0004905097,0.0004335748],"domain_scores_gemma":[0.9963551,0.000177436,0.002586812,0.0002147765,0.0003996395,0.0002662581],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.197969,0.0006052357,0.712371,0.0006905146,0.0004166676,0.00003563792,0.003400309,0.00014933,0.0003475951,4.077715e-8,0.00003014165,0.08398455],"study_design_scores_gemma":[0.04344217,0.02501291,0.9276953,0.002162198,0.0001754561,0.00005343634,0.0008296131,0.00008779568,0.0001685613,2.261933e-7,0.0001519048,0.0002204452],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969937,0.001034723,0.000008770741,0.0002378968,0.0001812225,0.001470049,0.00002120641,0.00001053229,0.00004184887],"genre_scores_gemma":[0.997381,0.000969771,0.001206372,0.0002587611,0.00001806108,0.00001143111,0.00001568551,0.00004241647,0.00009648591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2153243,"threshold_uncertainty_score":0.6554732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01673192590833185,"score_gpt":0.3429153850265056,"score_spread":0.3261834591181738,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}